News Tag: 2022 newsletters

NRG Oncology Trial Results Indicate Trametinib Should Represent the New Standard of Care for Women with Recurrent Low-Grade Serous Ovarian Cancer

Read More

Moving Research Forward through Legislative Advocacy

Read More

De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009, the “PREDICT-RT” Trial)

Read More

Phase 2 Double-Blinded Trial Combining Oligometastatic Radiotherapy with Androgen Deprivation Therapy (NRG-GU011)

Read More

NRG-CC005 “FORTE” Amendment #3 is Now Active

Read More

A Message from the Chairs of NRG Oncology’s Research Strategy Committee, 2021: The Year in Review

Read More

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer – Outcomes Presented Soon! (NRG-GY017)

Read More

Barbara Good, PhD, to Retire from NRG Oncology and the NSABP Foundation

Read More